Please assess the completion status of the following clinical trial:

Trial Title: Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to read and understand the informed consent document; must sign the informed consent.~2. Aged 18 to 75 years old , sex is not limited~3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection~4. Availability of at least 1 g tumor sample.~5. Karnofsky functional status rating \> or equal to 70.~6. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] ), and adequate renal function (BUN and creatinine \<1.5 times IULNs)~7. Agree to Surgical indications of Heart \& lung and without the coagulation system disease~8. Negative pregnancy test for female patients of childbearing potential~9. Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration~Exclusion Criteria:~1. Inability to comply with study-related procedures~2. patient not suitable for Neurosurgery.~3. Unavailability of at least 6 doses of vaccine~4. Progression prior to vaccination as determined by the Principal Investigator~5. Patient with allergic constitution~6. Unstable or severe intercurrent medical conditions~7. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection.~8. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids.~9. any other clinical trials within 30 days pre-vaccination.~10. Female patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- gp96 group (Type: EXPERIMENTAL): autologous gp96 vaccination + basal treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).